세계 암 면역치료 시장 규모는 2024년 1,442억 달러에서 예측 기간 동안 11.4%의 CAGR로 2029년 말에는 2,472억 달러에 달할 것으로 예상됩니다.
체크포인트 억제제 부문은 2024년 640억 달러에서 예측 기간 동안 11.0%의 CAGR로 2029년 말에는 1,078억 달러에 달할 것으로 예상됩니다. 단클론항체 부문은 2024년 445억 달러에서 예측 기간 동안 12.5%의 CAGR로 2029년 말에는 804억 달러에 달할 것으로 예상됩니다.
세계의 암 면역치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법·규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- Porter's Five Forces 분석
- 면역치료의 주요 개념
제3장 시장 역학
- 시장 역학
- 시장 성장 촉진요인
- 세계적인 암 환자 증가
- 면역치료제 승인
- 정부 자금과 의약품 연구개발비 증가
- 시장 성장 억제요인
- 면역치료의 고비용성
- 독점성 상실과 제네릭화
- 종양 전문가의 부족
- 시장 기회
- 면역치료의 기술 진보
- 암 면역치료의 가능성
제4장 규제 상황
제5장 신기술
- 개요
- AI
- 신흥 바이오마커
- 면역치료 파이프라인
- 특허 분석
- 향후 전망
제6장 시장 세분화 분석
- 세분화 내역
- 세계의 암 면역치료 시장 : 치료 유형별
- 세계의 시장 규모 및 예측
- 체크포인트 억제제
- 단클론항체
- 양자 세포 치료
- 사이토카인 요법
- 암백신
- 종양용해성 바이러스 요법
- 기타
- 세계의 암 면역치료 시장 : 암 유형별
- 세계의 시장 규모 및 예측
- 흑색종
- 백혈병
- 림프종
- 골수종
- 폐암
- 유방암
- 대장암
- 기타
- 지역적 내역
- 세계의 암 면역치료 시장 : 지역별
- 세계의 시장 규모 및 예측
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제7장 경쟁 정보
제8장 암 면역치료 시장의 지속가능성 : ESG 관점
- ESG : 개요
- 제약 업계에서 ESG의 역할
- 암 면역치료 시장의 지속가능성
- ESG의 관점
- 환경에 대한 영향
- 사회적 영향
- 거버넌스의 영향
- ESG 리스크 평가
- 결론
제9장 부록
- 조사 방법
- 약어
- 정보 출처
- 기업 개요
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
ksm
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
The cancer immunotherapy market for checkpoint inhibitors is expected to grow from $64.0 billion in 2024 and is projected to reach $107.8 billion by the end of 2029, at a CAGR of 11.0% during the forecast period of 2024 to 2029.
The cancer immunotherapy market for monoclonal antibodies is expected to grow from $44.5 billion in 2024 and is projected to reach $80.4 billion by the end of 2029, at a CAGR of 12.5% during the forecast period of 2024 to 2029.
Report Scope
This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy's current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024-2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.
In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.
The report aims to:
- Analyze therapies and types of cancer.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts for 2029.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the cancer immunotherapy market.
Report Includes
- 75 data tables and 54 additional tables
- An analysis of the global cancer immunotherapy market
- Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
- Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Threat of Substitutes
- Competitiveness in the Industry
- Key Concepts of Immunotherapy
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Rising Cancer Cases Globally
- Robust Approval of Immunotherapy Drugs
- Rise in Government Funding and Pharmaceutical R&D Spending
- Market Restraints
- High Cost of Immunotherapy
- Loss of Exclusivity and Genericization
- Shortage of Oncology Professionals
- Market Opportunities
- Technological Advances in Immunotherapy
- Potential in Cancer Immunotherapy
Chapter 4 Regulatory Landscape
- Overview
- U.S.
- Europe
- Japan
Chapter 5 Emerging Technologies
- Overview
- Artificial Intelligence (AI)
- Emergent Biomarkers
- Immunotherapy Pipeline
- Patent Analysis
- Future Prospects
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Cancer Immunotherapy, by Therapy Type
- Global Market Size and Forecast
- Checkpoint Inhibitors
- Monoclonal Antibodies
- Adoptive Cell Therapies
- Cytokine Therapy
- Cancer Vaccines
- Oncolytic Virus Therapy
- Other Immunotherapies
- Global Market for Cancer Immunology, by Cancer Type
- Global Market Size and Forecast
- Melanoma
- Leukemia
- Lymphoma
- Myeloma
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Other Cancers
- Geographic Breakdown
- Global Market for Cancer Immunotherapy, by Region
- Global Market Size and Forecast
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Overview
- Competitive Landscape
- Company Share Analysis
Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective
- Introduction to ESG
- Role of ESG in the Pharma Industry
- Sustainability in the Cancer Immunotherapy Market
- ESG Perspective
- Environmental Impact
- Social Impact
- Governance Impact
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
